Hypoglycaemic and related activities of a new pyrazolopyridine derivative (SQ 65,993).
D000284:Administration, Oral; D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D004357:Drug Synergism; D005260:Female; D005951:Glucose Tolerance Test; D006498:Hepatectomy; D006943:Hyperglycemia / Q000188:drug therapy; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D007328:Insulin / Q000494:pharmacology; D008099:Liver / Q000502:physiology; D008112:Liver Glycogen; D008297:Male; D051379:Mice; D010179:Pancreas / Q000502:physiology; D010180:Pancreatectomy; D011720:Pyrazoles / Q000008:administration & dosage / Q000627:therapeutic use; D011725:Pyridines / Q000008:administration & dosage / Q000627:therapeutic use*; D011817:Rabbits; D051381:Rats; D013453:Sulfonylurea Compounds / Q000008:administration & dosage / Q000627:therapeutic use*
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D008112:Liver Glycogen; D011720:Pyrazoles; D011725:Pyridines; D013453:Sulfonylurea Compounds